Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 499-502

  Awada, A ^a   Gil, T ^a   Sales, F ^a   Dubuisson, M ^a   Vereecken, P ^a   Klastersky, J ^a   Moerman, C ^a   De Valeriola, D ^a   Piccart, M J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Caelyx; Phase I; Solid tumors; Temozolomide

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; DEXAMETHASONE; DOXORUBICIN; LIPOSOME; SEROTONIN ANTAGONIST; TEMOZOLOMIDE;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN INJURY; CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE REDUCTION; ERYTHEMA; EWING SARCOMA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IRRADIATION; MALE; MELANOMA; NEUTROPENIA; PRIORITY JOURNAL; RASH; SARCOMA; STATISTICAL SIGNIFICANCE; STOMATITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; STOMATITIS; TREATMENT OUTCOME;

EID: 2942577651     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000127331.29310.8a     Document Type: Article

References (17)

1. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, et al. Temozolomide: a new oral cytotoxic chemotherapy agent with promising activity against primary brain tumours. Eur J Cancer 1993; 29A;940-942.
2. Middleton MR, Grab JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
3. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neuro-Oncol 2001; 53:259-265.
4. 6-alkylguanine DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer. Proc Am Soc Clin Oncol 1996; 15:178 (abstr).
5. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54:987-992.
6. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15:987-993.
7. Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Semin Oncol 2001; 28(suppl 12):32-40.
8. Volm M, Oratz R, Pavlick A, Farrell K, Lee J, Muggia F. A phase I study of liposomal doxorubicin and temozolomide in patients with advanced cancer. Proc Am Soc Clin Oncol 2000; 19:223 (abstr).
9. Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol Rep 1999; 6:1097-1099.
10. Vorabiof DA, Rapoport BL, Mahomed R, Karime M. Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Res 2003; 13:201-203.
11. Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002; 20:420-425.
12. Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 2002; 20:2610-2615.
13. Hwu WJ, Krown SE, Menell JH, Panageas KS, Merell J, Quinn CJ, et al. Temozolomide plus thalidomide in patients with advanced melanoma: a phase II trial. Proc Am Soc Clin Oncol 2002; 21:344 (abstr).
14. Danson S, Arance A, Lorigan P, Clamp A, Hodgetts J, Lomax L et al. A randomized study of temozolomide alone, with interferon-α or with thalidomide in metastatic malignant melanoma. Proc Am Soc Clin Oncol 2002; 21:343 (abstr).
15. Agarwala SS, Reyderman L, Statkevich P, Fraass U, Loomba A, Stover LL, et al. Pharmacokinetic study of temozolomide penetration into CSF in patient with durai melanoma. Ann Oncol 1998; 9(suppl 4):138 (abstr).
16. Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med 2001; 345:621-622.
17. Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH, Thatcher N, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002; 12:175-178.